Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
ART Suppresses Plasma HIV-1 RNA to a Stable Set Point Predicted by Pretherapy Viremia
- F. Maldarelli, S. Palmer, +15 authors J. Mellors
- Biology, Medicine
- PLoS pathogens
- 1 April 2007
Current antiretroviral therapy is effective in suppressing but not eliminating HIV-1 infection. Understanding the source of viral persistence is essential for developing strategies to eradicate HIV-1… Expand
Identification of Genotypic Changes in Human Immunodeficiency Virus Protease That Correlate with Reduced Susceptibility to the Protease Inhibitor Lopinavir among Viral Isolates from Protease…
- D. Kempf, J. Isaacson, +7 authors R. Rode
- Medicine, Biology
- Journal of Virology
- 15 August 2001
ABSTRACT The association of genotypic changes in human immunodeficiency virus (HIV) protease with reduced in vitro susceptibility to the new protease inhibitor lopinavir (previously ABT-378) was… Expand
Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.
Study M98-863 was a double-blind, randomized, phase 3 study that compared lopinavir/ritonavir with nelfinavir, each coadministered with stavudine and lamivudine, in 653 antiretroviral therapy-naive… Expand
Relative Replication Capacity and Selective Advantage Profiles of Protease Inhibitor-Resistant Hepatitis C Virus (HCV) NS3 Protease Mutants in the HCV Genotype 1b Replicon System
- Y. He, M. King, +6 authors A. Molla
- Medicine, Biology
- Antimicrobial Agents and Chemotherapy
- 17 December 2007
ABSTRACT We characterized the selective advantage profiles of a panel of hepatitis C virus (HCV) NS3 protease mutants with three HCV protease inhibitors (PIs), BILN-2061, ITMN-191, and VX-950, using… Expand
Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy.
- D. Kempf, J. Isaacson, +6 authors E. Sun
- Medicine
- Antiviral therapy
- 1 September 2002
The virological response of multiple protease inhibitor-experienced, non-nucleoside reverse transcriptase inhibitor-naive, HIV-1-infected subjects was examined with respect to baseline viral… Expand
Loss of Bone Mineral Density After Antiretroviral Therapy Initiation, Independent of Antiretroviral Regimen
- T. Brown, G. McComsey, M. King, R. Qaqish, B. M. Bernstein, B. D. da Silva
- Medicine
- Journal of acquired immune deficiency syndromes
- 1 August 2009
Background:Decreased bone mineral density (BMD) has been described in HIV-infected patients initiating antiretroviral therapy (ART), but the contributions of ART and immunologic and/or virologic… Expand
A Once-Daily Lopinavir/Ritonavir-Based Regimen Provides Noninferior Antiviral Activity Compared With a Twice-Daily Regimen
- M. Johnson, J. Gathe, +7 authors S. Brun
- Medicine
- Journal of acquired immune deficiency syndromes
- 1 October 2006
Objective:To evaluate the safety and noninferiority and to explore the efficacy of administration of once-daily versus twice-daily lopinavir/ritonavir (LPV/r) in antiretroviral-naive HIV-1-infected… Expand
Relationship between adherence and the development of resistance in antiretroviral-naive, HIV-1-infected patients receiving lopinavir/ritonavir or nelfinavir.
BACKGROUND
Relationships between adherence to protease inhibitor (PI)-based therapy and resistance development have not been fully characterized.
METHODS
We conducted a double-blind, randomized,… Expand
Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study
Objective: Combination antiretroviral therapy with lopinavir/ritonavir (LPV/r) has been highly effective in clinical trials. Results of long-term therapy with LPV/r-based regimens have not been… Expand
A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy.
- D. Cameron, B. D. da Silva, +7 authors G. Hanna
- Biology, Medicine
- The Journal of infectious diseases
- 15 July 2008
Antiretroviral-naive HIV-1-infected volunteers received zidovudine/lamivudine plus either lopinavir/ritonavir (n=104) or efavirenz (n=51). Lopinavir/ritonavir-treated subjects demonstrating 3… Expand